09724288 - GAU: 1649 NO. 1567 P. 10/18

MAY. 23. 2005 1::39PM TTC-PA 650-326-2422

TO THE OUT OF THE OUT

					PTO/SB/08A (08-03)
Substitut	e for farm 1449A	/PTO			Complete if Known
DIE C				Application Number	09/724,288
			LOSURE	Filing Date	November 28, 2000
STA	TEMENT	BY AP	PLICANT	First Named Inventor	Schenk, Dale B.
				Art Unit	1647
(use as many sheets as necessary)			cessary)	Examiner Name	Sharon L. Turner
Sheet	1	of	88	Attorney Docket Number	15270J-004765US

			U.S. PATENT D	OCUMENTS+	
		Document Number			
Examiner Initials*	Cité No.	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Clied Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	578	6,875,434	04-05-2005	Schank	Page of Applies
	577	6,866.849	03-15-2005	Schenk	
	575	6,866,850	03-15-2005	Schenk	
	576	6.818,218	11-16-2004	Schenk	
	563	6,787,637	09-07-2004	Schook et al.	
	572	6,761,888	07-13-2004	Schenk	
	562	6,750.324	06-15-2004	Schook et al.	
	573	6,743,427	06-01-2004	Schenk	
	444	2004/0043418 A1	03-04-2004	Holtzman et al.	
	544	2003/0147882 A1	08-07-2003	Solomon et al.	
	453	2002/0058267 A1	05-16-2002	Ozenberger et al.	
	511	6,331,440	12-18-2001	Nordstedt, et al.	
	516	6,261,569	07-17-2001	Comia et al	
	452	6.218,506 B1	04-17-2001	Krafft et al.	
	510	6,022,859	02-08-2000	Klessling, et al.	
	512	5,891,991	04-06-1999	Wasco et at.	
	445	5,854.215	12-29-1998	Findels et al.	
	446	5,817,626	10-06-1998	Findeis et al.	
	451	5,766,846	06-16-1998	Schlossmacher et al.	
	515	5,652,334	07-29-1997	Roberts	
	574	5.576,184	11-19-1996	Botter et al	
	513	5,514,548	05-07-1996	Krebber et al.	
	514	5,470,951	11-28-1995	Roberts	
	543	5,278,049	01-11-1994	Baker et al.	
	548	5.096,706	03-17-1992	Flint	
	570	4,912,206	03-27-1990	Goldgaber et al.	
				Date of Ct al.	
	_				
	-				
	-+				
-+	-				
-+					
-+	-+				
-+	-+				
_	-+				
	-				
	_				

_	
Examiner Signature	Date Considered

EXAMINET: Initial in Informo conditions whether or of dilation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered, include copy of the tom with not uncertainty of the conformance and not considered. Involved the conformance with MPEP 609. Draw the through citation if red in conformance with the conformance in the conformance and not conformance and the co

09724288 - GAU: 1649 NO. 1567 P. 11/18

MAY. 23. 2005 1:: 39PM

TTC-PA 650-326-2422

PTO/SB/08A (02.01)

Substit	ite for form 1449A	/РТО			Complete If Known
				Application Number	09/724,288
			LOSURE	Filing Date	November 28, 2000
STA	TEMENT	BY API	PLICANT	First Named Inventor	Schenk, Dale B.
				Art Unit	1647
	(use as many .	sneets as ne	cessary)	Examiner Name	Sharon L. Tumer
Sheet		of	8	Attorney Docket Number	15270J-004765US

Examiner	-	For	eign Patent Docume	DREIGN PA	1		Pages, Columns, Lines,	_
tritials*	Cite No.	Country Code ²		d Code (FA10411)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Otted Document	Where Relevant Passages or Relevant Figures Appear	١,
	533	AU_	199870091		07-01-1999		2 11 11	1
	523	EP	752 888	B1	01-28-1998			1-7
	579	wo	04/031400	A2	04-15-2004			۱ř
	571	wo	04/13172	A2, A3	02-12-2004			۲ř
	443	WO	03/74081	A1	09-12-2003			۱÷
	447	wo	03/51374	A2	08-26-2003			_
	458	WO	02/60481	A1	08-08-2002			1 5
	457	WO	02/46237	A1	06-13-2002			Ц
	557	wo	02/88307	A2	11-07-2002			H
	556	wo	02/88306	A2	11-07-2002			_
	456	WO	02/21141	A2	03-14-2002			
	450	WO	01/18169	A3				
	455	wo	01/10900	A2	03-15-2001			
	529	WO	00/68263	A2				
	519	WO	00/26238	A2	11-16-2000 05-11-2000			Ę
	555	WO	00/23082	A1	04-27-2000			Ę
	522	WO	00/20027	A2	04-27-2000			
	526	wo	99/06587	A2	02-11-1999			5
	454	WO	98/33815	A1	08-06-1998			
	520	wo	98/22120	A1	05-28-1998			ч
	530	wo	98/08868	A1	03-05-1998			Ц
	521	wo .	98/05350	A1	02-12-1998			ᆛ
	525	WO	98/02462	A1	01-22-1998			┝
	527	wo	97/32017	A1	09-04-1997			
	528	wo	97/08320	A1	03-06-1997			-
\neg	532	wo	96/37621	A2	11-28-1996			┾
	518	wo	95/23186	A1	08-31-1995			+
	531	wo	95/08999	A1	04-06-1995			ᅮ
	524	wo	95/05393	A2	02-23-1995			H
I	517	wo	94/05311	A1	03-17-1994			H

1	Examiner Signature	
-	Signature	Date Considered
	O-gridien o	Considered

EXAMNER: initial if retrement considered, whether or not clistion is in conformance with MPEP 609. Draw fire through classion if rest in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unless clisted designation number (splishments) and conformance and conformance and applicant's unless of the designation of the conformance and applicant in the conformance and applicant in the conformance and the document, the two-liketic materials and conformance and conformanc

09724288 - GAU: 1649

MAY. 23. 2005 1:39PM TTC-PA 650-326-2422

NO. 1567 P. 12/18

PTO/SH/08B (08-03)

Substitute fo	r form 1449B/7	OTO.		Complete if Known		
INFOR	MATIO	N DISC	LOSURE	Application Number	09/724,288	
				Fiting Date	November 28, 2000	
STATEMENT BY APPLICANT				First Named Inventor	Schenk, Dale B.	
				Art Unit	1647	
(us	(use as many sheets as necessary)			Examiner Name	Sharon L. Tumer	
Sheet	3	of	8	Attorney Docket Number	15270J-004765US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. ¹	include name of the author (in CAPITAL LETTERS), itils of the article (when appropriate), itile of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or oounity where published.	,
	448	ANDREW et al., Current Protocols in Immunology, 2.7.1-2.9.8, John Wiley & Sons, Inc. (1997).	T
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term Ag vaccination: Task specificity and correlations between Aß deposition and spatial memory," <u>DNA and Call Biology</u> , 20(11):737-744 (2001).	t
_	485	BACSKAI et al., "Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." Nature Medicine, 7(3):389-372 (2001).	T
	504	BALBACH et al., "Amytoid fibril formation by Ağı _{baz} , a seven-residue fragment of the Alzheimer's β- amytoid peptide, and structural characierization by solid state NMR," <u>Blochemistry</u> , 39:13748-13759 (2000).	r
	550	BARD et al., "Epitope and isotype specificities of antibodies to 8-amyloid peptide for protection against Alzheimer's disease-like neuropathology," <u>PNAS</u> , 100(4):2023-2028 (2003).	
	540	BENKIRANE, et al, "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D- Amino Acid Residues," J. Bloj. Chem., 268(23):26279-26285 (1993).	Г
	461	BURDICK et al., "Assembly and appreparation properties of synthetic Abheimer's AA/B arryloid peptide antigens," J. Biol. Chem., 267:543-555 (1992).	H
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Murant Form of Armyloid Precursor Protein 695," J. Biol.Chem., 276(24):21562-70 (2001).	-
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <u>J. Mol. Biol.</u> , 186:651-663 (1985).	
	509	CIRRITO et al., "Amyloid \$\mathcal{B}\$ and Alzhelmer disease therapeutics: the devil may be in the details," \(\frac{1}{2}\). Clin. invest112:321-323 (2000).	_
	462	CO et al., "Chimeric and humanized antibodies with specificity for the CO33 antigen," <u>J. Immund.</u> , 148:1149-1154 (1992).	
	541	CRIBBS et al, "All-D-Erantlomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta- Amyloids," J. Blol. Chem., 272:7431-7436 (1997).	_
	469	DEMATTOS et al., "Peripheral anti-A\$ antibody alters CNS and plasma clearance and decreases A\$ burden in a mouse model of Alzheimer's disease," PNAS, 98(15):8850-8855 (2001).	_
	493	DEMATTOS et al., "Plaque-associated disruption of CSF and plasma amyloid-\$ (A\$) equilibrium in a mouse model of Aizheimer's disease," J. Neurochem., 81:229-236 (2002).	_
\neg	486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β-amyloid 1-42 peptide." <u>DNA and Cell Biology</u> , 20(11):723-729 (2001).	_

	$\overline{}$		
	Examiner .	Date	
Į	Signature	Date	
3	Olgitatore	 Considered	1 1

EXAMENE, Initial 1 reformes considered, whether or not obtain it in conformance with MPEP 805. Draw the through distaller if not in conformance and not considered, find fundations on your that form with an comprehensive projection.]

Applicant's unlose distant despiration number (options). Figurinal to prize a clack mark hare if English Impuge Translation is stacked.

09724288 - GAU: 1649

MAY. 23. 2005 1:40PM TTC-PA 650-326-2422

NO. 1567 P. 13/18

PTO/SB/08B (01-03)

Substitute for	farm 1449B/F	то		Complete if Known		
INFOR	MATIO	N DISCI	OSHIDE	Application Number	09/724,288	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	November 28, 2000	
				First Named Inventor	Schenk, Dale B.	
				Art Unit	1647	
(use as many sheets as necessary)				Examiner Name	Sharon L. Turner	
Sheet	4	of	8	Attorney Docket Number	15270J-004765US	

	,	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), the of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, day and/or country where publisher.	7
	475	EL-AGNAF et al., 'The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide, 'Eur. J. Blochem. 256(3):560-559 (1998).	Ī
	501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β-zmyloid congener disrupts peptide folding and abolishes plaque competence," <u>Biochemistry</u> , 35:13914-13921 (1996).	r
	539	FINDEIS et al, "Modified peptide inhibitors of amyloid B-peptide polymertzation," <u>Blochemistry</u> , 38:6791-6800 (1999).	
	464	FLOOD et al., 'An amyloid β-Protein fragment, A β [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures,' <u>Brain Res.</u> 663(2):271-276 (1994).	r
	538	FLOOD, et al. Topography of a binding site for small amnestic peptides deduced from structure- activity studies: Relation to amnestic effect of amylold B protein," PNAS, 91:380-384 (1994).	
	565	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from Fundamental Immunology, fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1999).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <u>Biochem. J.</u> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of β-amyloid from Atzhekmer plaque effcit neuron killing in human microglia," <u>J Neurosci</u> , 16 (19):8021-8037 (1996).	
	503	GOREVIC et al., 'Ten to fourtieen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern' Bjochem, and Blonhy, Res. Commun., 147(2):854–862 (1987).	
_	487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders", "Nature Neuroscience, 4(9):859-860 (2001).	
	476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P- selectin." J. Immunoj, 160:1029-1035 (1998).	
	473	HILBICH et al., "Aggregation and secondary structure of synthetic amytold βΑ4 peptides of Alzheimer's disease," J. Mol. Bloj., 218:149-163 (1991).	
	471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amytoldogenicity of Alzheimer's disease BAA peptides" J. Mol. Blol., 228:480-473 (1992).	_
	534	HOCK et al., "Anlibodies against 8-Amytoid Stow Cognitive Decline in Alzheimer's Disease," Neuron, 38:542-554 (2003).	_
	546	IRIZARRY et al., "A# Deposition is Associated with Neuropii Changes, but not with Overt Neuronal Loss in the Human Amyloid Procursor Protein V717F (PDAPP) Transgenic Mouse," J. Neurosciance, 17(16):7033-7059 (1957).	_

Examiner Signature		Date Considered	
EVAMMED: Inlin	Al Wardenson and Tallet A. C. C.		

EXAMERS: Initial influence couldered, whether or not citation is in conformance with MPEP 909. Draw the through challon if not in conformance and not considered louised expert sites in sour communication to applicant.

Applicant's unique citation designation number optional. Planginess due piece a drack mark here if English language Translation is statched.

MAY. 23. 2005 1: 40PM TTC-PA 650-326-2422

09724288 - GAU: 1649 NO. 1567 P. 14/18

PTO/SB/06B (08-03)

Substitute fo	r form 1449B/P	то		Complete if Known		
INFOR	MATION	a nisci	LOSURE	Application Number	09/724,288	
			LICANT	Filing Date	November 28, 2000	
SIAIL	TIANTE LAID	OT APP	LICANI	First Named Inventor	Schenk, Dale B.	
				Art Unit	1647	
	e as many si	reets as ne	cessary)	Examinar Name	Sharon L. Tumer	
Sheet	_ 5	of	8	Attorney Docket Number	15270J-004765US	

	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	т
_	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A841 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94:1550-1555 (1997).	
	547	KAYED et al., "Conformational Transitions of Islet Amyloid Polypeptide (IAPP) in Amyloid Formation In Vitro," J. Mol. Biol., 287:781-796 (1999).	-
	554	KETTLEBOROUGH et al., "Humanization of a mouse monocional antibody by CDR-grafting: the importance of framework residues on loop conformation." Protein Engineering, 4(7):773-783 (1991).	۲
1.	488	KLEIN et al., 'Targeting small Aß ofigomers: the solution to an Alzhelmer's disease conundrum?,' Trends in Neurosciences, 24(4):219-224 (2001).	_
	494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <u>J.</u> Neurosci., 22(15):6331-6335 (2002).	
	465	KOUDINOV et al., "The soluble form of Alzheimer's amyfold beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <u>Biocham, 8 Biophys. Res.</u> Comm., 2051:164-171 (1994).	_
	478	KUO et al., 'High levels of circulating Abets42 are sequestered by plasma proteins in Alzheimer's disease, 'Biochem. Biochys. Res. Comm., 257(3):787-791 (1999).	_
	477	LAMBERT et al., "Diffusible, nonfibrilizar ligands derived from AB1-42 are potent central nervous system neurotoxins." PNAS, 95:6448-6453 (1998).	
	489	LAMBERT et al., "Vaccination with soluble Aß oligomers generates toxicity-neutralizing antibodies," J. Neurochem., 79.595-605 (2001).	
	490	LEE et al., "Aß immunization: Moving Aß poptide from brain to blood," PNAS, 98(16):8931-8932 (2001).	
	553	LEMERE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: Eschorionia colf. LT and LT(R192G) as mucosal adjuvants, "Neuroblology of Aging, 23(6):991-1000 (2002).	
	551	LEVERONE et al., 'Apri-15 is less immunogenic tran Apri-4042 for Intransact immunization of wild-type mice but may be effective for boosting'.' <u>Vaccine</u> , 21:2197-2208 (2003).	_
	459	LEVITT, M., "Molecular dynamics of native protein," J. Mol. Biol., 168:595-620 (1983).	-
	481	LEVY et al., "Immunization for Atzhelmer's disease: A shot in the arm or a whiff?," <u>American</u> Neurological Assoc. 48:553-554 (2000).	-
	499	LUE et al., "Soluble 8-amyloid Pepilde Concentration as a Predictor of Synaptic Change in Atzheimer's Disease," <u>Am. J. Pathol.</u> , 155:853-562 (1999).	

Examiner	Date
Signature	Considered
'CVALUED OF	

EXAMINE: nated in development consistend, whether or not classion is in conformance with MPEP 500. Draw fine through class of it conformance with MPEP 500. Draw fine through class of it conformance and not considered, bridge copy and committed conformance with MPEP 500. Draw fine through classifier if an another conformance with MPEP 500. Draw fine through classifier in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conformance with MPEP 500. Draw fine through class in conform

09724288 - GAU: 1649 NO. 1567 P. 15/18

MAY. 23. 2005 1:: 40 PM TTC-PA 650-326-2422

PTO/SB/03B (08-03)

Substitute for form 1449B/PTQ		Complete If Known		
INFORMATION DISCLOSUI	Application Number	09/724,288		
STATEMENT BY APPLICAN	Filing Date	November 28, 2000		
STATEMENT BY APPLICAL	First Named Inventor	Schenk, Dale B.		
	Art Unit	1647		
(use as many sheets as necessary)	Examiner Name	Sharon L. Turner		
Sheet 6 of 8	Attorney Docket Number	15270J-004765US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPIYAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(e), yolume-issue number(s), publisher, dry and/or country where published.	т
	502	MAGGIO et al., "Brain Amyloid – A Physicochemical Perspective," Brain Pathology, 6:147-162 (1996).	Γ
	545	MASLIAH et al., "Comparison of Neurodogenerative Pathology in Transgenic Mice Overexpressing V1717 B-Amyloid Procursor Protein and Alzhelmer's Disease," J. Neurosolence, 19(18):5795-5811 (1999).	
	479	MCLEAN et al., "Soluble pool of A\$ arryloid as a determinant of severity of neurodegeneration in Abzheimer's disease." <u>Amer. Neurological Assoc.</u> , 46:860-866 (1999).	l
	482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," J. Am. Med. Assoc., 283:1571 (2000).	
568	568	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of Immunoglobulin V _t -V _h and V _t -V _t domain dimmers," <u>PNAS</u> , 82:4592-4598 (1985).	
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856	-
	491	PODUSLO et al., "Permeability of proteins at the blood-brein barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," Neurobiol, Dis., 8(4):555-567 (2001).	_
	460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," FNAS, 86:10029-10033 (1989).	
	497	RAGUSI et al., "Redistribution of Impramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," J. Neurochem., 70(5):2099-2105 (1998).	_
	466	SCHWARZMAN et al., "Transthyretin sequesters amyloid β protein and prevents amyloid formation," PNAS, 91:8366-8372 (1994).	
	536	SELA et al, "Different roles of D-amino acids in immune phenomena," <u>FASEB J.</u> 11(6):449-456 (1999)	-
\Box	552	SIGUROSSON et al., *Immunization with a Nontoxic/Nonfibrillar Amyloid- ß Homologous Peptide Reduces Alzhalmer's Disease-Associated Pathology in Trasngenic Mice,* Am. J. Pathology. 159(2):493-47 (2001).	_
	505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neuroloxic activity in vitro," Molecular Pharmacology, 45:373-379 (1994).	
	549	SOLOMON, 6., "Immunological approaches as therapy for Alzheimer's disease," Expert Opin, Biol. Ther., 2(8):907-917 (2002).	-
	508	SOTO et al., 'The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β- peptide modulates amyloid formation.' <u>J. Biol. Chem.</u> 270(7):3053-3067 (1995).	-

Examiner	Dat	to The state of th
Signature		nsidered
TOTAL COLUMN TO A SEC		ilisidei ed

EASHINER, Initial Internacio considersi, wholler or not claison is in conformance with MPEP 600, Draw line through classion if not in conformance with MPEP 600, Draw line through classion if not in condormance and not considerate included congruence and complication is applicant.

Applicant's unique citation designation number (spilarus) - Applicant is unique a check mark here If English language Translation is statemed.

09724288 - GAU: 1649 NO. 1567 P. 16/18

MAY. 23. 2005 1:41PM TTC-PA 650-326-2422

PTO/SB/03B (08-03)

substitute fo	or form 1449B/P	το			Complete if Known
INFOR	MATIO	ושפותו	.OSURE	Application Number	09/724,288
			LICANT	Filing Date	November 28, 2000
SIAIL	TIAICIA!	ST APP	LICANI	First Named Inventor	Schenk, Dale B.
				Art Unit	1647
(use as many sheets as necessary)				Examiner Name	Sharon L. Turner
Sheet	7	of	8	Attorney Docket Number	15270J-004765US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), bits of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calatiog, etc.), date, page(s), volume-issue number(s), publisher, chy and/or country where publisher.	7
	496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", Neuroendocrinology, 58:210-217 (1993).	T
	498	SUO et al., "Scluble Alznelmers β-amyfold constricts the cerebral vasculature in vivo" <u>Neuroscience</u> <u>Letters</u> . 257:77-80 (1998).	T
	467	TABATON et al., "Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <u>Blochem.</u> and <u>Blophys.</u> Res. Comm., 200(3):1598-1603 (1994).	†
	472	TELLER et al., "Presence of soluble amyloid β-peptide precedes arryfold plaque formation in Down's syndrome" Nature Medicine, 2(1):93-95 (1995).	T
	500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β-peptide fibril formation," <u>J. Biol. Chem.</u> , 274(18):12619-12625 (1999).	t
	537	TJERNBERG, et al. "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," J. Biol Chem. 272(19):12601-12605 (1997).	┢
_	492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid-β ₁₋₂ " Neurosci. Lett. 307:101-104 (2001).	\vdash
	535	VAN REGENMORTEL et al., 'D-peptides as immunogens and diagnostic reagents,' Curr. Opin. Biotechnol., 9(4):377-382 (1998).	-
	569	VERSHIGORA A. E. OBSHCHAYA IMMYNOLOGIYA, pages 35, 229-231 and 152-153. 1990	
	480	WANG et al., "The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging," Experimental Neurology, 158:328-337 (1999).	\vdash
	495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rate daniate gyrus," <u>Brain Resparch</u> , 924:133-140 (2002).	
	474	WINTER et al., "Humanized antibodies" Immunology Today, 14(6):243-246 (1996).	-
	468	WISNIEWSKI et al., "Alzhelmer's disease and soluble A beta," Neurobiol, Aging, 15(2):143-52 (1984).	-
	506	WOOD et al., "Profines and amyloidogenicily in fragments of the Alzhaimer's peptide B/A4" Biochemistry, 34:724-730 (1995).	
	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Benca Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity"," J. Exp. Med., 132:211- 250, (1970).	
	507	XU at al., "increased incidence of anti-β-amyloid autoanthodies secreted by Epatein-Barr virus transformed B cell lines from patients with Alzhalmer's disease," Machanisms of Ageing and Development 94:213-22 (1997).	_

Examiner	Date	$\overline{}$
Signature	Considered	- 1
SVALUNGO, 1 III 1 II	7.000.00	- 1

EXAMINE: hital inference consistent, whether or not classon is in conformance with MPEP 600. Draw time should instant in conformance and not considered, included copy of the later with rest communication is applicant.

Applicant's unique clusten designation number (portious). Placificant to piace check much then if Englat inapuse Translation is attached.

09724288 - GAU: 1649 NO. 1567 P. 17/18

MAY, 23, 2005 1:41PM TTC-PA 650-326-2422

PTO/SB/08B (08-03)

Súbsülule fo	r form 1449B/PTC	1		Complete If Known		
INFOR	MATION	DISCI	OSHDE	Application Number	09/724,288	
	MENT B			Filing Date	November 28, 2000	
SIAIL	INICIALID	APP	LICANI	First Named Inventor	Schenk, Dale B.	
				Art Unit	1647	
	e as many she	ets as ne	essary)	Examinar Name	Sharon L. Tumer	
Sheet	8	of	8	Attorney Docket Number	15270J-004765US	

(book, magazine, journal, senai, symposium, catalog, etc.), data nane(s) volume issue number						
483	ZLOKOVIC et al., "Clearance of amyloid β-peptide from brain: transport or metabolism?," Nature Medicine, 6(7):718-719 (2000).					
580	ZLOKOVIC et al. "Giycoprotein 330/megatin; probabte role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers, "PNAS, 36(1)(4229-4344 (1998) abstract only,	1				
	No.1 483	Citie include rome of the author (in CAPTAL LETTERS), title of the article (when appropriate), title of the item (No.) policy, regizine), journel, acted, appropriate, racialog, dec, deta, page(se), volume-less number(s), volume regizine, and regizine (in the propriate regizine). A CONCOVIC et al., "Clearamaco of arriginal page(se) from brain: transport or metabolism?", Nature Madicine, (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism? (1900 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism? (1900 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) from brain: transport or metabolism?", Nature 2000 (677-16-17-6) policy of arriginal page(se) policy of arrigi				

Examiner	/Daniel Kolker/	Date	00/40/0000	$\overline{}$
Signature		Considered	03/18/2009	
		Considered	1	

EXAMINES Initial Informer considered, whether or not distant is in conformance with MPEP 808. Draw line through distant if not in conformance with MPEP 808. Draw line through distant if not in conformance and not considered, or not considered to produce it.

Applicant's unique citation designation number (picked). Supplicant to prise or check mark harm if English language Transition is stacked.